Biology of Blood and Marrow Transplantation
Volume 12, Issue 12 , Pages 1285-1294 , December 2006

Regression of Myelofibrosis and Osteosclerosis following Hematopoietic Cell Transplantation Assessed by Magnetic Resonance Imaging and Histologic Grading

  • George E. Sale

      Affiliations

    • Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Departments of Medicine and Pathology, Seattle Cancer Care Alliance, Seattle, Washington
    • ,
  • H. Joachim Deeg

      Affiliations

    • Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Departments of Medicine and Pathology, Seattle Cancer Care Alliance, Seattle, Washington
    • Corresponding Author InformationCorrespondence and reprint requests: H. Joachim Deeg, MD, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1-100, Seattle, WA 98109-1024.
    • ,
  • Bruce A. Porter

      Affiliations

    • First Hill Diagnostic Imaging, Seattle, Washington

Received 7 June 2006 ,Accepted 21 July 2006.

References 

  1. Hoffman R. Agnogenic myeloid metaplasia. In:  Hoffman R,  Benz EJ,  Shattil SJ,  Furie B,  Cohen HJ,  Silberstein LE,  McGlave P editor. Hematology: Basic Principles and Practice. New York: Churchill Livingstone; 2000;p. 1172–1188
  2. Tefferi A. Chronic myeloid disorders: Classification and treatment overview (review). Semin Hematol. 2001;38(suppl 2):1–4
  3. Platzbecker U, Gooley T, Anasetti C, et al. Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation. Leuk Lymphoma. 2002;43:1409–1414
  4. Kroger N, Zabelina T, Schieder H, et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol. 2005;128:690–697
  5. Rondelli D, Barosi G, Bacigalupo A, et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood. 2005;105:4115–4119
  6. Deeg HJ, Gooley TA, Flowers MED, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood. 2003;102:3912–3918
  7. Rajantie J, Sale GE, Deeg HJ, et al. Adverse effect of severe marrow fibrosis on hematological recovery after chemoradiotherapy and allogeneic bone marrow transplantation. Blood. 1986;67:1693–1697
  8. Doney KC, Buckner CD, Thomas ED, et al. Allogeneic bone marrow transplantation for chronic granulocytic leukemia. Exp Hematol. 1981;9:966–971
  9. Soll E, Massumoto C, Clift RA, et al. Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment. Blood. 1995;86:4667–4673
  10. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study. Blood. 1999;93:2831–2838
  11. Bauermeister DE. Quantitation of bone marrow reticulin—a normal range. Am J Clin Pathol. 1971;56:24–31
  12. Dekmezian R, Kantarjian HM, Keating MJ, Talpaz M, McCredie KB, Freireich EJ. The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer. 1987;59:1739–1743
  13. Deeg HJ, Storer BE, Boeckh M, et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant. 2006;12:573–584
  14. Bornhäuser M, Storer B, Slattery JT, et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood. 2003;102:820–826
  15. Jurado M, Deeg HJ, Storer B, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant. 2002;8:161–169
  16. Stuart MJ, Cao TM, Sandmaier BM, et al. Efficacy of non-myeloablative allogeneic transplant for patients with myelodysplastic syndrome (MDS) and myeloproliferative disorders (MPD) (except chronic myelogenous leukemia). Blood. 2003;102(Pt 1):185a;Abstract 644
  17. Anderson JE, Tefferi A, Craig F, et al. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. Blood. 2001;98:586–593
  18. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood. 1996;88:1013–1018
  19. Olipitz W, Beham-Schmid C, Aigner R, Raith J, Linkesch W, Sill H. Acute myelofibrosis: multifocal bone marrow infiltration detected by scintigraphy and magnetic resonance imaging. Ann Hematol. 2000;79:275–278
  20. Gualdi GF, Di Biasi C, Serafini G, Casciani E. The role of MRI in the valuation of disorders involving the bone marrow. [in Italian] Clin Ter. 1997;148:407–417

PII: S1083-8791(06)00494-0

doi: 10.1016/j.bbmt.2006.07.008

Biology of Blood and Marrow Transplantation
Volume 12, Issue 12 , Pages 1285-1294 , December 2006

Article Tools

* Image Usage & Resolution